Synthesis, characterization and antiviral evaluation of 1,3-Thiazolidine-4-one derivatives bearing L-Valine side chain;L-Valin yan zinciri taşıyan 1,3-tiyazolidin-4-on türevlerinin sentezi, yapılarının aydınlatılması ve antiviral etkilerinin tespiti

Marmara Pharmaceutical Journal

Volumn 16, Issue 3, 2012, Pages 181-193

  Tatar, Esra ^a   Küçükgüzel, Ilkay ^a   De Clercq, Erik ^b   Krishnan, Ramalingam ^c   Kaushik Basu, Neerja ^c  

^a MARMARA UNIVERSITY   (Turkey)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

4 Thiazolidinones; Anti HCV activity; Anti HIV activity; L valine

Indexed keywords

EID: 84878776107     PISSN: None     EISSN: 13090801     Source Type: Journal    
DOI: 10.12991/201216397     Document Type: Article

References (54)

1. Kline T, Barry KC, Jackson SR, Felise HB, Nguyen HV, Miller SI. Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system. Bioorg Med Chem Lett 2009; 19: 1340-3.
2. Felise HB, Nguyen HV, Pfuetzner RA, Barry KC, Jackson SR, Blanc MP, Bronstein PA, Kline T, Miller SI. An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 2008; 4: 325-36.
3. Küçükgüzel G, Kocatepe A, De Clercq E, Sahin F, Güllüce M. Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. Eur J Med Chem 2006; 41: 353-9.
4. Puratchikody A, Natarajan R, Jayapal M, Doble M. Synthesis, in vitro antitubercular activity and 3D-QSAR of novel quinoxaline derivatives. Chem Biol Drug Des 2011; 78: 988-98.
5. Vintonyak VV, Warburg K, Kruse H, Grimme S, Hübel K, Rauh D, Waldmann H. Identification of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase B. Angew Chem Int Ed Engl 2010; 49: 5902-5.
6. Tatar E, Küçükgüzel İ, Küçükgüzel ŞG, Yi{dotless}lmaz-Demircan F, De Clercq E, Andrei G, Snoeck R, Pannecouque C, Şahin F, Bayrak ÖF. Synthesis, anti-tuberculosis and antiviral activity of novel 2-isonicotinoylhydrazono-5-arylidene-4-thiazolidinones. Int J Drug Des Dis 2010; 1: 19-32.
7. Küçükgüzel SG, Oruç EE, Rollas S, Sahin F, Özbek A. Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds. Eur J Med Chem 2002; 37: 197-206.
8. El Bialy SA, Nagy MM, Abdel-Rahman HM. antiviral and anticancer. Efficient regioselective three-component domino synthesis of 3-(1,2,4-triazol-5-yl)-1,3-thiazolidin-4-ones as potent antifungal and antituberculosis agents. Arch Pharm (Weinheim) 2011; 344: 821-9.
9. Rojas Ruiz FA, García-Sánchez RN, Estupiñan SV, Gómez-Barrio A, Torres Amado DF, Pérez-Solórzano BM, Nogal-Ruiz JJ, Martínez-Fernández AR, Kouznetsov VV. Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds. Bioorg Med Chem 2011; 19: 4562-73.
10. Ravichandran V, Jain A, Kumar KS, Rajak H, Agrawal RK. Design, synthesis, and evaluation of thiazolidinone derivatives as antimicrobial and anti-viral agents. Chem Biol Drug Des 2011; 78: 464-70.
11. Barreca ML, Chimirri A, De Luca L, Monforte AM, Monforte P, Rao A, Zappalà M, Balzarini J, De Clercq E, Pannecouque C, Witvrouw M. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg Med Chem Lett 2001; 11: 1793-6.
12. Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalà M. Synthesis and anti-HIV activity of 2,3-diary1,3-thiazolidin-4-ones. Il Farmaco 2003; 58: 115-20.
13. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalà M. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Res 2004; 63: 79-84.
14. Rawal RK, Prabhakar YS, Katti SB, De Clercq E. 2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIVRT inhibitors. Bioorg Med Chem 2005; 13: 6771-6.
15. Rawal RK, Tripathi R, Kati SB, Pannecouque C, De Clercq E. Design, synthesis and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg Med Chem 2007; 15: 1725-31.
16. Rawal RK, Kumar A, Siddiqi MI, Katti SB. Molecular docking studies on 4-thiazolidinones as HIV-1 RT inhibitors. J Mol Model 2007; 13: 155-61.
17. Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Eur J Med Chem 2008; 43: 2800-6.
18. Chen H, Bai J, Jiao L, Guo Z, Yin Q, Li X. Design, microwave-assisted synthesis and HIV-RT inhibitory activity of 2-(2,6-dihalophenyl)-3-(4,6-dimethyl-5-(un)substituted-pyrimidin-2-yl)thiazolidin-4-ones. Bioorg Med Chem 2009; 17: 3980-6.
19. Balzarini J, Orzeszko-Krzesińska B, Maurin JK, Orzeszko A. Synthesis and anti-HIV studies of 2-and 3-adamantyl-substituted thiazolidin-4-ones. Eur J Med Chem 2009; 44: 303-11.
20. Kaushik-Basu N, Bopda-Waffo A, Talele TT, Basu A, Chen Y, Kucukguzel SG. 4-Thiazolidinones: a novel class of hepatitis C virus NS5B polymerase inhibitors. Front Biosci 2008; 13: 3857-68.
21. Rawal RK, Kati SB, Kaushik-Basu N, Arora P, Pan Z. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependent RNA polymerase: 2-Aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives. Bioorg Med Chem Lett 2008; 18: 6110-4.
22. Lemm JA, O'Boyle DR, Liu M, Nower PT, Colonno R, Deshpande MS, Snyder LB, Martin SW, St Laurent DR, Serrano-Wu MH, Romine JL, Meanwell NA, Gao M. Identification of hepatitis C virus NS5A inhibitors. J Virol 2010; 84: 482-91.
23. Lemm JA, Leet JE, O'Boyle DR, Romine JL, Huang XS, Schroeder DR, Alberts J, Cantone JL, Sun JH, Nower PT, Martin SW, Serrano-Wu MH, Meanwell NA, Snyder LB, Gao M. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrob Agents Chemtherap 2011; 55: 3795-802.
24. Keller TH, Shi PY, Wang QY. Anti-infectives: can cellular screening deliver? Curr Opin Chem Biol 2011; 15: 529-33.
25. Chen X, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X. Synthesis and biological evaluation of piperidinesubstituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. Eur J Med Chem 2012; 51:60-6.
26. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009; 33: 307-20.
27. Camarasa MJ, Velázquez S, San-Félix A, Pérez-Pérez MJ, Gago F. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes. Antiviral Res 2006; 71: 260-7.
28. De Clercq E. A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 2011; 51: 1-24.
29. Barreca ML, Rao A, De Luca L, Zappalà M, Monforte AM, Maga G, Pannecouque C, Balzarini J, De Clercq E, Chimirri A, Monforte P. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J Med Chem 2005; 48: 3433-7.
30. Menéndez-Arias L, Betancor G, Matamoros T. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antiviral Res 2011; 92: 139-49.
31. Mao Y, Li Y, Hao M, Zhang S, Ai C. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors. J Mol Model 2012; 18: 2185-98.
32. Tatar E, Küçükgüzel İ, De Clercq E. 3-[2-(Arylamino)-3-methylbutanamido]-2-aryl-5-substituted/non-substituted-1,3-thiazolidine-4-ones as antiviral agents. 5th International Symposium on Pharmaceutical Chemistry, September 5-7, 2007, İstanbul, Turkey, Published in: Turkish Journal of Pharmaceutical Sciences, Special Issue, 2007.
33. Tatar E, Küçükgüzel İ, De Clercq E. Synthesis, characterisation and antiviral activity of novel 1,3-thiazolidine-4-ones derived from new 1-[2-(benzoylamino)-3-metylbutyryl]-4-alkyl/arylalkyl thiosemicarbazides. 5th International Symposium on Pharmaceutical Chemistry, September 5-7, 2007, İstanbul, Turkey, Published in: Turkish Journal of Pharmaceutical Sciences, Special Issue, 2007.
34. Küçükgüzel İ, Tatar E, Küçükgüzel ŞG, Rollas S, De Clercq E. Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/ aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. Eur J Med Chem 2008; 43: 381-92.
35. Tatar E, Küçükgüzel İ, De Clercq E, Şahin F, Güllüce M. Synthesis, characterization and screening of antimicrobial, antituberculosis, antiviral and anticancer activity of novel 1,3-thiazolidine-4-ones derived from 1-[2-(benzoylamino)-4-(methylthio)butyryl]-4-alkyl/ arylalkyl thiosemicarbazides. Arkivoc 2008; 14: 191-210.
36. Giret MT, Kallas EG. GBV-C: state of the art and future prospects. Curr HIV/AIDS Rep 2012; 9: 26-33.
37. Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS 2011; 6: 501-7.
38. Barnabas RV, Webb EL, Weiss HA, Wasserheit JN. The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS 2011; 25: 1559-73.
39. Karrer P, Van der Sluys VFC. The configuration of natural valine. Helv Chim Acta 1932; 15: 746-50.
40. Applewhite TH, White H, Niemann C. α-Chymotrypsincatalysed hydrolysis of acetyl-, chloroacetyl-, and benzoyl-L-valine methyl ester. J Am Chem Soc 1958; 80: 1465-9.
41. Slebioda M, St-Amand MA, Chen FMF, Benoiton NL. Studies on the kinetics of racemization of 2,4-disubstituted-5(4H)-oxazolones. Can J Chem 1988; 66: 2540-4.
42. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20: 309-21.
43. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS, Science 1984; 224: 497-500.
44. Barré-Sinoussi F, Chermann JC, Nugeyre MT, Chamaret S, Grest J, Dauget C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
45. Miyoshi I, Taguchi H, Kobonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y, Akagi T. TypeC-virus-producing cell lines derived from adult T cell leukaemia. Gann Monogr 1982; 28: 219-28.
46. De Clercq E, Descamps J, Verhelst G, Walker RT, Jones AS, Torrence PF, Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis 1980; 141: 563-74.
47. De Clercq E. Antiviral and antimetabolic activities of neplanocins. Antimicrob Agents Chemother 1985; 28: 84-9.
48. De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal P. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323: 464-7.
49. Kaushik-Basu N, Bopda-Waffo A, Talele TT, Basu A, Costa PR, da Silva AJ, Sarafianos, SG, Noel F. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res 2008; 36: 1482-96.
50. Archana, Srivastava VK, Kumar A. Synthesis of newer thiadiazolyl and thiazolidinonyl quinazolin-4(3H)-ones as potential anticonvulsant agents. Eur J Med Chem 2002; 37: 873-82.
51. Wrobel J, Jetter J, Kao W, Rogers J, Di L, Chi J, Peréz MC, Chen GC, Shen ES. 5-Alkylated thiazolidinones as follicle-stimulating hormone (FSH) receptor agonists. Bioorg Med Chem 2006; 14: 5729-41.
52. Rehse K, Lüdtke E. Z/E Isomerism in Thiazole-and 1,3,4-Thiadiazole-2-nitrosimines. Arch Pharm (Weinheim) 1992; 327: 647-51.
53. Çapan G, Ulusoy N, Ergenç N, Kiraz M. New 6-phenylimidazo[2,1-b]thiazole derivatives: Synthesis and antifungal activity. Monatsh Chem 1999; 130: 1399-407.
54. Marković R, Baranac M, Juranić N, Macura S, Cekić I, Minić D. 1H-NMR Dynamic study of thermal Z/E isomerization of 5-substituted 2-alkylidene-4-oxothiazolidine derivatives: Barriers to rotation about C=C bond. J Mol Struc 2006; 800: 85-92.